By Anna Ringstrom and Maggie Fick STOCKHOLM/LONDON (Reuters) -Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ...

Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the ...

Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the ...

New health technology assessment (HTA) statistics produced by Denmark’s Medicine Council (Medicinrådet) for 2024 have ...

Denmark’s biggest pension fund, ATP, is taking a major hit on its 2.3 billion-krone ($324 million) stake in troubled battery ...

The coming year brings both good and bad for homeowners in Denmark. While valuations are now back at peak levels, mortgage ...

Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) announced plans to invest approximately $1.20 billion (8.5 billion ...

Novo’s latest investment comes just days after the U.S. FTC greenlit the highly contentious acquisition of Catalent, which ...

Ozempic maker Novo Nordisk A/S is investing 8.5 billion kroner ($1.2 billion) to build a new major factory in Denmark to help ...

Danish pharma giant Novo Nordisk will make a significant investment of approximately $1.2 billion to construct a new ...

For most Scandinavian vineyards, solaris is the grape of choice - an aromatic, hybrid variety that's well-adapted to colder ...

Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, which have gained ...